TRIGR Therapeutics, Inc.

TRIGR Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments targeting unmet medical needs in the field of cancer and autoimmune diseases. Founded in 2018, TRIGR Therapeutics, Inc. is based in Irvine, California, US, where it operates as an independent entity.

The company specializes in therapeutic solutions designed to address critical health challenges. George Uy serves as the CEO and founder of the firm. TRIGR Therapeutics successfully secured funding in an Add-on, Trade Sale round, raising USD 45. 20 mn led by Compass Therapeutics, Inc.

, bringing the total amount raised to USD 5. 00 mn across three deals, with the most recent occurring on May 11, 2021. TRIGR Therapeutics, Inc. focuses on developing therapeutic products aimed at treating cancer and autoimmune diseases.

Their research prioritizes innovative methodologies to enhance patient care and outcomes, tailoring solutions for both individual and clinical applications. The company's approach involves rigorous scientific validation to ensure effective treatment protocols are developed for diverse patient demographics. TRIGR Therapeutics, Inc. generates revenue through strategic collaborations and partnerships within the biotech sector.

The exact pricing models and subscription structures are not publicly disclosed but emphasize accessibility and comprehensive support for healthcare solutions. Looking ahead, TRIGR Therapeutics is strategizing to introduce new therapeutic products aimed at significantly improving treatment outcomes for patients with cancer and autoimmune diseases. Expansion plans include targeting international markets beginning in 2024, focusing on Europe and Asia, where the demand for innovative therapies is growing. The recent funding of USD 45.

20 mn will be allocated to accelerate research and development efforts, ensuring the timely launch of these new products.